Michael Goldberg

CEO at Surge Therapeutics

After graduating Summa Cum Laude with an Hon. B.Sc. in Biological Chemistry from the University of Toronto, Michael completed a M.Phil. in BioScience Enterprise at the University of Cambridge and a Ph.D. in Biological Chemistry at the Massachusetts Institute of Technology (MIT) under the mentorship of Dr. Robert Langer. Michael conducted his post-doctoral training in the Koch Institute for Integrative Cancer Research at MIT under the guidance of Nobel Laureate Phillip Sharp.

Before founding SURGE, Michael was an assistant professor of Cancer Immunology & Virology at the Dana-Farber Cancer Institute and of Microbiology and Immunobiology at Harvard Medical School. Having lost several friends to post-surgical cancer recurrence, he felt a moral obligation to focus full-time on translating to patients a novel approach that could address this tremendous unmet medical need. In addition to earning 25 awards and a number of distinguished grants, Michael has published in Cell, Nature, Nature Biotechnology, Nature Reviews Cancer, Science, and Science Translational Medicine.

Michael’s leadership in the field has been recognized by multiple awards, including an appointment to the Harvard Medical School Leadership Development for Physicians and Scientists.


Previous companies

Dana-Farber Cancer Institute logo


  • CEO

    Current role